Cytomed Therapeutics Ltd. (GDTC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cytomed Therapeutics Ltd. (GDTC:NASDAQ), powered by AI.

Current Price
$1.14
Sector
Healthcare
What is the Cytomed Therapeutics Ltd. stock price forecast?

Cytomed Therapeutics Ltd. is currently trading at $1.14. View real-time AI analysis on Alpha Lenz.

What is Cytomed Therapeutics Ltd. insider trading activity?

View the latest insider trading data for Cytomed Therapeutics Ltd. on Alpha Lenz.

What is Cytomed Therapeutics Ltd.'s P/E ratio?

View Cytomed Therapeutics Ltd.'s valuation metrics on Alpha Lenz.

Cytomed Therapeutics Ltd.

NASDAQ · GDTC
$1.14+0.07(+6.54%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Cytomed Therapeutics Ltd.'s future dividend policy...
Alpha Chat Insight

Cytomed Therapeutics Ltd.'s ROE is -51.3%. Explore profitability and growth together.

Ask for details

Company Overview

Cytomed Therapeutics Ltd. is a biotechnology company dedicated to the research, development, and commercialization of novel medical therapies. The company's primary focus is on creating innovative treatments for unmet medical needs, often targeting rare diseases and complex conditions with limited existing therapeutic options. By leveraging cutting-edge biotechnological techniques, Cytomed aims to advance healthcare solutions that improve patient outcomes and quality of life. This company operates at the intersection of life sciences and healthcare, making significant impacts in biotechnology and pharmaceutical sectors. It seeks collaborative partnerships with academic institutions, research organizations, and healthcare providers to accelerate its drug development pipeline and bring effective therapies to market. Cytomed Therapeutics Ltd. plays a crucial role in the biopharmaceutical industry by pushing the boundaries of medical science and contributing to the advancement of personalized medicine. In the financial markets, Cytomed represents a dynamic player within the biotechnology sector, attracting interest due to its potential for groundbreaking medical advancements. The company's progress in clinical trials and regulatory approvals can significantly influence its market position and investor perceptions.

CEODr. Wee Kiat Tan Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees43

Company Statistics

FY 2025

Profile

N/AMarket Cap
$324.39KRevenue
0.00Shares Out
43Employees

Margins

79.04%Gross
-1144.98%EBITDA
-1307.60%Operating
-1231.97%Pre-Tax
-1231.97%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-44.27%ROA
-51.33%ROE
-44.04%ROIC

Financial Health

$2.10MCash & Cash Equivalents
$-964.20KNet Debt
16.51%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Cytomed Therapeutics Ltd. (ticker: GDTC) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 43 employees.

The current price is $1.14 with a P/E ratio of -x and P/B of -x.

ROE is -51.33% and operating margin is -1307.60%. Annual revenue is $324,387.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Cytomed Therapeutics Ltd. (GDTC) Stock Forecast 2026 $1.14 — Price, Financials & Analyst Targets | Alpha Lenz